Your browser doesn't support javascript.
loading
Optical photothermal infrared spectroscopy for nanochemical analysis of pharmaceutical dry powder aerosols.
Khanal, Dipesh; Kim, Jinhee; Zhang, Jing; Ke, Wei-Ren; Holl, Mark M Banaszak; Chan, Hak Kim.
Afiliação
  • Khanal D; Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia.
  • Kim J; Department of Chemical & Biological Engineering, Monash University, Clayton, Victoria 3800, Australia.
  • Zhang J; Department of Chemical & Biological Engineering, Monash University, Clayton, Victoria 3800, Australia.
  • Ke WR; School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
  • Holl MMB; Department of Chemical & Biological Engineering, Monash University, Clayton, Victoria 3800, Australia; Department of Mechanical and Materials Engineering, University of Alabama at Birmingham, Birmingham, AL 35294, USA; Division of Pulmonology, Allergy, and Critical Care Medicine, Heersink School
  • Chan HK; Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia. Electronic address: kim.chan@sydney.edu.au.
Int J Pharm ; 632: 122563, 2023 Feb 05.
Article em En | MEDLINE | ID: mdl-36586629
ABSTRACT
The aim of this research was to chemically analyse the distribution of drugs and excipients in pharmaceutical dry powder inhalation (DPI) aerosol particles of various sizes in solid state. The conventional wet assay of the chemical composition of particles after collection in a cascade impactor lacks the capability to differentiate spatially resolved morphology and chemical composition of particles in complex DPI formulations. In this proof-of-concept study, we aim to demonstrate the feasibility of using optical photothermal infrared spectroscopy (O-PTIR) to characterize micro- to nano-scale chemical composition of size-segregated particles of pharmaceutical DPI formulations. These formulations were prepared by spray drying a solution or a suspension comprising an inhaled corticosteroid fluticasone propionate, a long-acting ß2-agonist salmeterol xinafoate, and excipient lactose. The active ingredients fluticasone propionate and salmeterol xinafoate are widely used for the treatment of asthma and chronic obstructive pulmonary disease. Spatially resolved O-PTIR spectra acquired from the particles collected from stages 1-7 of a Next Generation Impactor (NGI) for both formulations confirmed the presence of peaks related to fluticasone propionate (1746 cm-1, 1702 cm-1, 1661 cm-1 and 1612 cm-1), salmeterol xinafoate (1582 cm-1), and lactose (1080 cm-1). There was no significant difference in the drug to lactose peak ratio among various size fractions of particles spray dried from solution indicating a homogeneity in drug and lactose content in the aerosol formulation. In contrast, the suspension-spray dried formulation showed the drug content increased while the lactose content decreased in the particles collected down the NGI from stage 1 to stage 7, indicating heterogeneity in the ratio of drug-excipient distribution. The qualitative chemical compositions from O-PTIR were comparable to conventional wet chemical assays of various size fractions, indicating the suitability of O-PTIR to serve as a valuable analytical platform for screening the physicochemical properties of DPIs in solid state.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Excipientes / Lactose Tipo de estudo: Qualitative_research Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Excipientes / Lactose Tipo de estudo: Qualitative_research Idioma: En Ano de publicação: 2023 Tipo de documento: Article